Biosimilar medicines are structurally not exact copies of the original biologic drug and hence, are not generics. The idea of developing a biosimilar was to provide alternative products, with similar efficacy, at a lower cost than the original biological medicines (like etanercept, infliximab, and adalimumab).  Biosimilars have comparable quality, safety, and effectiveness to biologicals from which they have been derived. The amino acid sequence, potency, dosing, route of administration and clinical effects are identical in both biosimilars and biologicals.